{"id":282,"date":"2012-04-24T12:00:00","date_gmt":"2012-04-24T12:00:00","guid":{"rendered":"https:\/\/nolato.wpengine.com\/?mfn_news=positive-development-for-all-business-areas"},"modified":"2012-04-24T12:00:00","modified_gmt":"2012-04-24T12:00:00","slug":"positive-development-for-all-business-areas","status":"publish","type":"mfn_news","link":"https:\/\/temporary.nolato.com\/ru\/mfn_news\/positive-development-for-all-business-areas\/","title":{"rendered":"Positive development for all business areas"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/strong><\/div>\n<p><span>In today\u2019s year-end report, Nolato has reported sales for the first quarter of 2012 of SEK 837 million (759), representing a 10% increase. Operating profit (EBITA) was up 30% to SEK 57 million (44) and earnings per share rose to SEK 1.41 (1.06). <\/span><\/p>\n<p><span>&#34;We are pleased to report positive development for all business areas,&#34; says Hans Porat, President and CEO of Nolato. <\/span><\/p>\n<p><span>Nolato Medical\u2019s sale rose by 6% to SEK 246 million (232), operating profit (EBITA) increased to SEK 31 million (28) and the EBITA margin was 12.6% (12.1). <\/span><\/p>\n<p><span>&#34;Product sales developed well in line with the growth in the market during the quarter, while project-related sales remained lower,&#34; comments Hans Porat. <\/span><\/p>\n<p><span>Nolato Telecom\u2019s sales rose by 11% to SEK 287 million (259), operating profit (EBITA) increased to SEK 7 million (-4) and the EBITA margin was 2.4% (-1.5). <\/span><\/p>\n<p><span>&#34;The start-up of new customer projects from March onwards is progressing as planned, which will gradually replace the older product portfolio,&#34; says Hans Porat. <\/span><\/p>\n<p><span>Nolato Industrial&#39;s sales rose by 13% to SEK 304 million (268), operating profit (EBITA) increased to SEK 28 million (25) and the EBITA margin was a strong 9.2% (9.3). <\/span><\/p>\n<p><span>&#34;Capacity utilisation was high during the quarter,&#34; says Hans Porat. &#34;Demand was stable, and new products, particularly within the area of hygiene, have experienced a positive development.&#34;<\/span><\/p>\n<p><span>Cash flow after investments was, as a result of the increase in sales, SEK \u201332 million (+111). Net debt totalled SEK 112 million (\u201380) and the equity\/assets ratio was 53% (54). <\/span><\/p>\n<p><span>Nolato has after the balance sheet date acquired the company Cope Allman Jaycare, see the press release of 11 April. The company is a British company within pharmaceutical packaging and provides geographic expansion and a stronger customer base for Nolato Medical. For 2012 the company is considered to have sales of approx. SEK 270 million.<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span><em>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<br \/><\/em><\/span><span><em>For further information, please contact:\u00a0<br \/><\/em><\/span><span><em>Hans Porat, President and CEO, telephone 46 431 442294\u00a0<\/em><\/span><br \/><span><em>Per-Ola Holmstr\u00f6m, Executive Vice President and CFO, telephone 46 431 442293<\/em><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>In today\u2019s year-end report, Nolato has reported sales for the first quarter of 2012 of SEK 837 million (759), representing a 10% increase. Operating profit (EBITA) was up 30% to SEK 57 million (44) and earnings per share rose to SEK 1.41 (1.06). &#34;We are pleased to report positive development for all business areas,&#34; says&hellip; <a class=\"more-link\" href=\"https:\/\/temporary.nolato.com\/ru\/mfn_news\/positive-development-for-all-business-areas\/\">Continue reading <span class=\"screen-reader-text\">Positive development for all business areas<\/span><\/a><\/p>\n","protected":false},"template":"","class_list":["post-282","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn","mfn-news-tag-mfn-report-interim-q1","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-report","entry"],"translation":{"provider":"WPGlobus","version":"3.0.0","language":"ru","enabled_languages":["en","es","de","fr","ru","sv"],"languages":{"en":{"title":true,"content":true,"excerpt":false},"es":{"title":false,"content":false,"excerpt":false},"de":{"title":false,"content":false,"excerpt":false},"fr":{"title":false,"content":false,"excerpt":false},"ru":{"title":false,"content":false,"excerpt":false},"sv":{"title":false,"content":false,"excerpt":false}}},"_links":{"self":[{"href":"https:\/\/temporary.nolato.com\/ru\/wp-json\/wp\/v2\/mfn_news\/282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/temporary.nolato.com\/ru\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/temporary.nolato.com\/ru\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/temporary.nolato.com\/ru\/wp-json\/wp\/v2\/media?parent=282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}